Compounds

Details Compounds Compounds

2011-03-29

2011-03-29

Bernhardt, Emily (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S372000, C544S379000, C544S396000, C514S252130, C514S254050, C514S254100

Reexamination Certificate

active

07915413

ABSTRACT:
The invention relates to at least one compound of general formula Iwherein R1is phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, or pyridine N-oxide, where each R1phenyl and R1heteroaromatic ring may optionally and independently be substituted by 1, 2 or 3 substituents selected from CF3, methyl, iodo, bromo, fluoro, and chloro; R2is independently selected from ethyl and isopropyl;R3is hydrogen or fluoro; R4is —NH2or —NHSO2R5; and R5is hydrogen, —CF3, or C1-C6alkyl, or pharmaceutically acceptable salts thereof, at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one δ receptor associated condition with at least one compound in accordance with Formula I; and at least one pharmaceutical composition comprising at least one compound in accordance with Formula I.

REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 4778789 (1988-10-01), Fex et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5658908 (1997-08-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5840896 (1998-11-01), Van Belle et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 7030124 (2006-04-01), Chang et al.
patent: 7229994 (2007-06-01), Brown et al.
patent: 7253173 (2007-08-01), Brown et al.
patent: 2004/0138228 (2004-07-01), Plobeck et al.
patent: 2006/0030569 (2006-02-01), Brown et al.
patent: 2006/0142296 (2006-06-01), Brown et al.
patent: 2006/0167004 (2006-07-01), Brown et al.
patent: 2007/0249619 (2007-10-01), Brown et al.
patent: 2007/0254890 (2007-11-01), Brown et al.
patent: 2007/0293502 (2007-12-01), Brown et al.
patent: 2431178 (1975-01-01), None
patent: 2900810 (1980-07-01), None
patent: 0133323 (1985-02-01), None
patent: 0166302 (1986-01-01), None
patent: 0283310 (1988-09-01), None
patent: 0289227 (1988-11-01), None
patent: 0624584 (1998-08-01), None
patent: 2696744 (1994-04-01), None
patent: 2076403 (1981-12-01), None
patent: 2210366 (1989-06-01), None
patent: 215847 (1999-04-01), None
patent: 217619 (2000-03-01), None
patent: 7138230 (1995-05-01), None
patent: 8604584 (1986-08-01), None
patent: 9107967 (1991-06-01), None
patent: 9204338 (1992-03-01), None
patent: 9206971 (1992-04-01), None
patent: 9315062 (1993-08-01), None
patent: 9504051 (1995-02-01), None
patent: 9626196 (1996-08-01), None
patent: 9723466 (1997-07-01), None
patent: 9828270 (1998-07-01), None
patent: 9828275 (1998-07-01), None
patent: 9901033 (1999-01-01), None
patent: 9933806 (1999-07-01), None
patent: 0001375 (2000-01-01), None
patent: 0145637 (2001-06-01), None
patent: 0146174 (2001-06-01), None
patent: 0146263 (2001-06-01), None
patent: 0174805 (2001-10-01), None
patent: 02094786 (2002-11-01), None
patent: 02094794 (2002-11-01), None
patent: 02094812 (2002-11-01), None
patent: 03029215 (2003-04-01), None
patent: 03094853 (2003-11-01), None
patent: 2004041800 (2004-05-01), None
patent: 2004041801 (2004-05-01), None
patent: 2004041802 (2004-05-01), None
patent: 2004062562 (2004-07-01), None
patent: 2005066148 (2005-07-01), None
patent: 2006014133 (2006-02-01), None
patent: 2006091160 (2006-08-01), None
Nortey et a. Bioorganic & Medicinal Chemistry Letters, vol. 11, p. 1741-1743 (2001).
Snyder et al. Trends in Pharmacological Sciences, vol. 24, p. 198-205 (2003).
Adriaensen, H. et al., “Clinical Review of Oral Drug Treatments for Diabetic Neuropathic Pain-Clinical Outcomes Based on Efficacy and Safety Data from Placebo-Controlled and Direct Comparative Studies,” Diabetes Metab. Res. Rev., 2005, 21(3), pp. 231-240.
Banker, G. et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Bilsky, E. et al., “SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist,” Journal of Pharmacology and Experimental Therapeutics, 1995, vol. 273, pp. 359-366.
Bilsky, E. et al., “Characterization of Enantiomers of (+)BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Regulatory Peptides, 1994, vol. 54, pp. 25-26.
Burkey, T. et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Life Sciences, 1998, vol. 62, Nos. 17/18, pp. 1531-1536.
Calderon, S. et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(R)-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide Delta Opioid Receptor Agonist,” J. Med. Chem., 1994, vol. 37, pp. 2125-2128.
Calderon, S. et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis, Opioid Receptor Binding, and Bioassay of the Highly Selective Delta Agonist (+)-4-[(R)-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and Related Novel Nonpeptide Delta Opioid Receptor Ligands,” J. Med. Chem., 1997, vol. 40, pp. 695-704.
Chang, K. et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” The Journal of Pharmacology and Experimental Therapeutics, 1993, vol. 267, No. 2, pp. 852-857.
Davis, MP et al., “Controversies in Pharmacotherapy of Pain Management,” Lancet Oncol., 2005, 6(9), pp. 696-704.
Filliol, D. et al., “Mice deficient for delta- and mu-opioid receptors exhibit opposing alternations of emotional responses,” Nature Genetics, 2000, vol. 25, pp. 195-200.
Greene, T. et al., “Protective Groups in Organic Synthesis,” 1981, pp. 267-268 and 331.
Katrizky, A. et al., “Benzotriazole-mediated Arylalkylation and Heteroarylalkylation,” Chemical Society Reviews, 1994, pp. 363-373.
Kingsbury, W. et al., “Synthesis of Structural Analogs of Leukotriene B4 and Their Receptor Binding Activity,” J. Med. Chem., 1993, vol. 36, pp. 3308-3320.
Lopez, J. et al., “Exploring the Structure-Activity Relationships of [1-(4-tert-Butyl-3′-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective Delta Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem., 1999, vol. 42, pp. 5359-5368.
Nagase, H. et al., “The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (−) TAN-67 on Pain Modulation,” Life Sciences, 2001, vol. 68, pp. 2227-2231.
Plobeck, N. et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Delta Opioid Receptor Agonists with Increased In Vitro Metabolic Stability,” J. Med. Chem., 2000, vol. 43, pp. 3878-3894.
Przewlocki, R. et al., “Opioids in Neuropathic Pain,” Curr. Pharm. Des. 2005, 11(23), pp. 3013-3025.
Saitoh, A., “Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavorial models in rodents,” J. Pharmacol. Sci., 2004, vol. 95, pp. 374-380.
Suggs, J. et al., “Facile Synthesis of 8-Substituted Quinolines,” J. Org. Chem., 1980, vol. 45, pp. 1514-1515.
Takemori, A. et al., “Selective Natrexone-Derived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol., 1992, vol. 32, pp. 239-269.
Vippagunta, S. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
West, A., “Solid State Chemistry and its Applications,” Wiley, New York, 1988, pp. 358 & 365.
Wolff, M., “Burger's Medicinal Chemistry and Drug Discovery, 5ed, Part 1,” John Wiley & Sons, 1995, pp. 975-977.
Zhang, X. et al., “Probes for Narcotic Receptor Mediated Phenomena. 26.1-3 Synthesis and Biological Evaluation of Diarylmethylpiperazines and Diarylmethylpiperidines as Novel, Nonpeptidic Delta Opioid Receptor Ligands,” J. Med. Chem., 1999, vol. 42, pp. 5455-5463.
International S

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2620707